Jemincare has advanced its PKD drug candidate JMKX003142 into multiple Phase 1 studies, with the most recent — a drug-drug interaction study (NCT07565441) — estimated to begin recruiting in May 2026. This follows two other registered Phase 1 studies: a QTc interval study (NCT07470177) and a mass balance/absolute bioavailability study (NCT07463053).
The registration of multiple early-phase pharmacology studies suggests Jemincare is building the complete pharmacokinetic profile required to advance JMKX003142 toward Phase 2 efficacy trials. Drug-drug interaction studies are typically among the last Phase 1 requirements before advancing to patient trials.
Limited information is publicly available about JMKX003142's mechanism of action or preclinical results. The drug is being developed in China, and no publications in English-language journals have emerged yet. However, the pace of clinical study registration indicates active and well-funded development.
For PKD patients, JMKX003142 represents another pipeline candidate with potential, though it remains early-stage with no efficacy data in humans. The global PKD community will be watching for mechanism disclosure and plans for international trials.